JP2004534755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534755A5 JP2004534755A5 JP2002589470A JP2002589470A JP2004534755A5 JP 2004534755 A5 JP2004534755 A5 JP 2004534755A5 JP 2002589470 A JP2002589470 A JP 2002589470A JP 2002589470 A JP2002589470 A JP 2002589470A JP 2004534755 A5 JP2004534755 A5 JP 2004534755A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- phenyl
- diazepan
- hydrochloride
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- -1 Cinnamoyl Chemical group 0.000 claims 12
- 208000008589 Obesity Diseases 0.000 claims 10
- 235000020824 obesity Nutrition 0.000 claims 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000001350 alkyl halides Chemical class 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Chemical group 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 2
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000003636 chemical group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YBVFGIVGPAJLHK-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-n-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)N(C)C(C(=C1)NS(C)(=O)=O)=CC=C1N1CCCNCC1 YBVFGIVGPAJLHK-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- UFVNNBAKIVCCJV-UHFFFAOYSA-N 2-(1,4-diazepan-1-yl)-5-(3,4-dihydro-1h-isoquinolin-2-ylsulfonyl)aniline;dihydrochloride Chemical compound Cl.Cl.NC1=CC(S(=O)(=O)N2CC3=CC=CC=C3CC2)=CC=C1N1CCCNCC1 UFVNNBAKIVCCJV-UHFFFAOYSA-N 0.000 claims 1
- OXPGVPJGNUTOIJ-UHFFFAOYSA-N 2-(1,4-diazepan-1-yl)-5-(3,4-dihydro-2h-quinolin-1-ylsulfonyl)aniline;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NC1=CC(S(=O)(=O)N2C3=CC=CC=C3CCC2)=CC=C1N1CCCNCC1 OXPGVPJGNUTOIJ-UHFFFAOYSA-N 0.000 claims 1
- IAVOMOLJEUUEJJ-UHFFFAOYSA-N 2-(1,4-diazepan-1-yl)-5-morpholin-4-ylsulfonylaniline;hydrochloride Chemical compound Cl.NC1=CC(S(=O)(=O)N2CCOCC2)=CC=C1N1CCCNCC1 IAVOMOLJEUUEJJ-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- JRABVEPQBHTNEB-UHFFFAOYSA-N 3-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=C(N2CCNCCC2)C(NS(=O)(=O)C=2C=CC=CC=2)=CC=1S(=O)(=O)NC1=CC=CC=C1 JRABVEPQBHTNEB-UHFFFAOYSA-N 0.000 claims 1
- BQJGPBTZYNGMTH-UHFFFAOYSA-N 3-amino-2-chloro-n-naphthalen-1-yl-4-piperazin-1-ylbenzenesulfonamide Chemical compound NC1=C(Cl)C(S(=O)(=O)NC=2C3=CC=CC=C3C=CC=2)=CC=C1N1CCNCC1 BQJGPBTZYNGMTH-UHFFFAOYSA-N 0.000 claims 1
- FYGYVBUXDONVKW-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(2,5-dimethylphenyl)benzenesulfonamide Chemical compound CC1=CC=C(C)C(NS(=O)(=O)C=2C=C(N)C(N3CCNCCC3)=CC=2)=C1 FYGYVBUXDONVKW-UHFFFAOYSA-N 0.000 claims 1
- YIEMYULZHPOHDR-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(2-methoxyphenyl)benzenesulfonamide Chemical compound COC1=CC=CC=C1NS(=O)(=O)C(C=C1N)=CC=C1N1CCNCCC1 YIEMYULZHPOHDR-UHFFFAOYSA-N 0.000 claims 1
- JJDPZXRUIVQMDK-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(3-fluoro-2-methoxyphenyl)benzenesulfonamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.COC1=C(F)C=CC=C1NS(=O)(=O)C(C=C1N)=CC=C1N1CCNCCC1 JJDPZXRUIVQMDK-UHFFFAOYSA-N 0.000 claims 1
- SAUZITPHYKKGRB-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(3-fluorophenyl)benzenesulfonamide Chemical compound NC1=CC(S(=O)(=O)NC=2C=C(F)C=CC=2)=CC=C1N1CCCNCC1 SAUZITPHYKKGRB-UHFFFAOYSA-N 0.000 claims 1
- XLKMIAYZWUNVHK-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(3-methoxyphenyl)benzenesulfonamide Chemical compound COC1=CC=CC(NS(=O)(=O)C=2C=C(N)C(N3CCNCCC3)=CC=2)=C1 XLKMIAYZWUNVHK-UHFFFAOYSA-N 0.000 claims 1
- QRMJOOKTGVZCJI-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(4-methoxyphenyl)benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1NS(=O)(=O)C(C=C1N)=CC=C1N1CCNCCC1 QRMJOOKTGVZCJI-UHFFFAOYSA-N 0.000 claims 1
- GRCSUIIMHXGBJI-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-(4-methylphenyl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1NS(=O)(=O)C(C=C1N)=CC=C1N1CCNCCC1 GRCSUIIMHXGBJI-UHFFFAOYSA-N 0.000 claims 1
- DEHKDJZMLDFXCM-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-methyl-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=C(N2CCNCCC2)C(N)=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 DEHKDJZMLDFXCM-UHFFFAOYSA-N 0.000 claims 1
- XWTGZLBSOQBINS-UHFFFAOYSA-N 3-amino-4-(1,4-diazepan-1-yl)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.NC1=CC(S(=O)(=O)NC=2C=CC=CC=2)=CC=C1N1CCCNCC1 XWTGZLBSOQBINS-UHFFFAOYSA-N 0.000 claims 1
- IHYHRJXVPAXBLE-UHFFFAOYSA-N 3-amino-4-(3-methylpiperazin-1-yl)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1CNC(C)CN1C1=CC=C(S(=O)(=O)NC=2C=CC=CC=2)C=C1N IHYHRJXVPAXBLE-UHFFFAOYSA-N 0.000 claims 1
- NUEOVOLDSBQFFU-UHFFFAOYSA-N 3-amino-4-(4-ethylpiperazin-1-yl)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1CN(CC)CCN1C1=CC=C(S(=O)(=O)NC=2C=CC=CC=2)C=C1N NUEOVOLDSBQFFU-UHFFFAOYSA-N 0.000 claims 1
- GVSUDVZBAQYBOA-UHFFFAOYSA-N 3-amino-4-(4-methyl-1,4-diazepan-1-yl)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1CN(C)CCCN1C1=CC=C(S(=O)(=O)NC=2C=CC=CC=2)C=C1N GVSUDVZBAQYBOA-UHFFFAOYSA-N 0.000 claims 1
- JLMXYYCQKXBTGS-UHFFFAOYSA-N 3-amino-n-(2-chlorophenyl)-4-(1,4-diazepan-1-yl)benzenesulfonamide Chemical compound NC1=CC(S(=O)(=O)NC=2C(=CC=CC=2)Cl)=CC=C1N1CCCNCC1 JLMXYYCQKXBTGS-UHFFFAOYSA-N 0.000 claims 1
- FHPZBWWLSCRQPJ-UHFFFAOYSA-N 3-amino-n-(3-chlorophenyl)-4-(1,4-diazepan-1-yl)benzenesulfonamide Chemical compound NC1=CC(S(=O)(=O)NC=2C=C(Cl)C=CC=2)=CC=C1N1CCCNCC1 FHPZBWWLSCRQPJ-UHFFFAOYSA-N 0.000 claims 1
- BUNZFNATZFRHOM-UHFFFAOYSA-N 3-amino-n-phenyl-4-piperazin-1-ylbenzenesulfonamide;hydrochloride Chemical compound Cl.NC1=CC(S(=O)(=O)NC=2C=CC=CC=2)=CC=C1N1CCNCC1 BUNZFNATZFRHOM-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- CVCBYAPWYGLGSN-UHFFFAOYSA-N 4-(1,4-diazepan-1-yl)-3-(methanesulfonamido)-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(S(=O)(=O)NC=2C=CC=CC=2)=CC=C1N1CCCNCC1 CVCBYAPWYGLGSN-UHFFFAOYSA-N 0.000 claims 1
- CJMASYSSFWANNC-UHFFFAOYSA-N 4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-3-amino-n-(2-methoxyphenyl)benzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=CC=C1NS(=O)(=O)C(C=C1N)=CC=C1N1CC2CCCN2CC1 CJMASYSSFWANNC-UHFFFAOYSA-N 0.000 claims 1
- XMCXZCACDJSZGQ-UHFFFAOYSA-N 4-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-3-amino-n-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=C(N2CC3CCCN3CC2)C(N)=CC=1S(=O)(=O)NC1=CC=CC=C1 XMCXZCACDJSZGQ-UHFFFAOYSA-N 0.000 claims 1
- XGKGXIWSMCPQQW-UHFFFAOYSA-N 4-chloro-n-[5-(4-methyl-1,4-diazepan-1-yl)-2-nitrophenyl]benzenesulfonamide Chemical compound C1CN(C)CCCN1C1=CC=C([N+]([O-])=O)C(NS(=O)(=O)C=2C=CC(Cl)=CC=2)=C1 XGKGXIWSMCPQQW-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical group N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 claims 1
- RFEWGXFJJSWGGZ-UHFFFAOYSA-N acetic acid;2-[3-amino-4-(1,4-diazepan-1-yl)phenyl]sulfonylbenzamide Chemical compound CC(O)=O.CC(O)=O.NC(=O)C1=CC=CC=C1S(=O)(=O)C(C=C1N)=CC=C1N1CCNCCC1 RFEWGXFJJSWGGZ-UHFFFAOYSA-N 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- ODVBYGKHVGIJOU-UHFFFAOYSA-N n-(2-amino-4-piperazin-1-ylphenyl)-3-fluorobenzenesulfonamide Chemical compound NC1=CC(N2CCNCC2)=CC=C1NS(=O)(=O)C1=CC=CC(F)=C1 ODVBYGKHVGIJOU-UHFFFAOYSA-N 0.000 claims 1
- PZQNRGJRFSLRNK-UHFFFAOYSA-N n-(4-amino-3-piperazin-1-ylphenyl)benzenesulfonamide Chemical compound C1=C(N2CCNCC2)C(N)=CC=C1NS(=O)(=O)C1=CC=CC=C1 PZQNRGJRFSLRNK-UHFFFAOYSA-N 0.000 claims 1
- XANFNWPZLJAOCV-UHFFFAOYSA-N n-(4-nitro-3-piperazin-1-ylphenyl)benzenesulfonamide Chemical compound C1=C(N2CCNCC2)C([N+](=O)[O-])=CC=C1NS(=O)(=O)C1=CC=CC=C1 XANFNWPZLJAOCV-UHFFFAOYSA-N 0.000 claims 1
- YDYABFVXSAOHTL-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-2,1,3-benzoxadiazole-4-sulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C3=NON=C3C=CC=2)=CC=1N1CCCNCC1 YDYABFVXSAOHTL-UHFFFAOYSA-N 0.000 claims 1
- IPWXILJLPMFMRF-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-2,4,6-trimethylbenzenesulfonamide;hydrochloride Chemical compound Cl.CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 IPWXILJLPMFMRF-UHFFFAOYSA-N 0.000 claims 1
- NPUAYJWTUOGONW-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-2,5-dimethoxybenzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(S(=O)(=O)NC=2C(=CC(=CC=2)N2CCNCCC2)NS(=O)(=O)C=2C=CC=CC=2)=C1 NPUAYJWTUOGONW-UHFFFAOYSA-N 0.000 claims 1
- XADLAHNCVSFSCC-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide;hydrochloride Chemical compound Cl.CC1=NOC(C)=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 XADLAHNCVSFSCC-UHFFFAOYSA-N 0.000 claims 1
- WPROYZRPQCTUSR-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-4-butoxybenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(OCCCC)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 WPROYZRPQCTUSR-UHFFFAOYSA-N 0.000 claims 1
- NUBFAPLYMNVBKK-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-4-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 NUBFAPLYMNVBKK-UHFFFAOYSA-N 0.000 claims 1
- XSUPQKCOFZZPIF-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-4-methylsulfonylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(S(=O)(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 XSUPQKCOFZZPIF-UHFFFAOYSA-N 0.000 claims 1
- GKUGYOYYBBFMHV-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-4-phenylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=C(C=2C=CC=CC=2)C=CC=1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 GKUGYOYYBBFMHV-UHFFFAOYSA-N 0.000 claims 1
- ZPHHDOAAXLFOFN-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-5-(dimethylamino)naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 ZPHHDOAAXLFOFN-UHFFFAOYSA-N 0.000 claims 1
- VEOHAQSHRONNRY-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]-5-fluoro-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CC1=CC=C(F)C=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 VEOHAQSHRONNRY-UHFFFAOYSA-N 0.000 claims 1
- SQKWYZRAQFWPAE-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 SQKWYZRAQFWPAE-UHFFFAOYSA-N 0.000 claims 1
- XKQQZDWFFNBRPR-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=CC=1N1CCCNCC1 XKQQZDWFFNBRPR-UHFFFAOYSA-N 0.000 claims 1
- HIWYWMDAICBRTA-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]naphthalene-2-sulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)=CC=1N1CCCNCC1 HIWYWMDAICBRTA-UHFFFAOYSA-N 0.000 claims 1
- MHWJWMJSUDQQBI-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-(1,4-diazepan-1-yl)phenyl]quinoline-8-sulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=CC=1N1CCCNCC1 MHWJWMJSUDQQBI-UHFFFAOYSA-N 0.000 claims 1
- FKHLEGQCZVSWCG-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2,4,6-trimethylbenzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 FKHLEGQCZVSWCG-UHFFFAOYSA-N 0.000 claims 1
- AWQGTSVAHFRBDI-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2,4-difluorobenzenesulfonamide Chemical compound FC1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 AWQGTSVAHFRBDI-UHFFFAOYSA-N 0.000 claims 1
- YHJZADCUNJRKAR-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2,5-dimethoxybenzenesulfonamide Chemical compound COC1=CC=C(OC)C(S(=O)(=O)NC=2C(=CC(=CC=2)N2CCNCC2)NS(=O)(=O)C=2C=CC=CC=2)=C1 YHJZADCUNJRKAR-UHFFFAOYSA-N 0.000 claims 1
- YKUZGTKBSULKAA-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2-methoxy-4-methylbenzenesulfonamide Chemical compound COC1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 YKUZGTKBSULKAA-UHFFFAOYSA-N 0.000 claims 1
- LNQLZGMOFVYNDA-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2-methylbenzenesulfonamide Chemical compound CC1=CC=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 LNQLZGMOFVYNDA-UHFFFAOYSA-N 0.000 claims 1
- YMABHSWGVLONQV-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-2-methylsulfonylbenzenesulfonamide Chemical compound CS(=O)(=O)C1=CC=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 YMABHSWGVLONQV-UHFFFAOYSA-N 0.000 claims 1
- FHNWRSGDPHETAK-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide Chemical compound CC1=NOC(C)=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 FHNWRSGDPHETAK-UHFFFAOYSA-N 0.000 claims 1
- WBQDCETZDTVJDX-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-4-butoxybenzenesulfonamide Chemical compound C1=CC(OCCCC)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 WBQDCETZDTVJDX-UHFFFAOYSA-N 0.000 claims 1
- PCAXUKBJYSESNW-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-4-methoxy-2-methylbenzenesulfonamide Chemical compound CC1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 PCAXUKBJYSESNW-UHFFFAOYSA-N 0.000 claims 1
- ZQHAHDQGZFTEMW-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 ZQHAHDQGZFTEMW-UHFFFAOYSA-N 0.000 claims 1
- BKSYGSPXBRAATP-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-4-methylsulfonylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 BKSYGSPXBRAATP-UHFFFAOYSA-N 0.000 claims 1
- JPEZHTHWWWHEQU-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-5-(dimethylamino)naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 JPEZHTHWWWHEQU-UHFFFAOYSA-N 0.000 claims 1
- JSCDSQDNRVXDNZ-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]-5-fluoro-2-methylbenzenesulfonamide Chemical compound CC1=CC=C(F)C=C1S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 JSCDSQDNRVXDNZ-UHFFFAOYSA-N 0.000 claims 1
- BOIKEIGQIBCDGM-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]naphthalene-1-sulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)=CC=1N1CCNCC1 BOIKEIGQIBCDGM-UHFFFAOYSA-N 0.000 claims 1
- BVIBTQYYWPYZKT-UHFFFAOYSA-N n-[2-(benzenesulfonamido)-4-piperazin-1-ylphenyl]quinoline-8-sulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C(=CC=1)NS(=O)(=O)C=2C3=NC=CC=C3C=CC=2)=CC=1N1CCNCC1 BVIBTQYYWPYZKT-UHFFFAOYSA-N 0.000 claims 1
- QPUFHIPBJRUGOU-UHFFFAOYSA-N n-[2-(ethylamino)-4-piperazin-1-ylphenyl]-3-fluorobenzenesulfonamide Chemical compound CCNC1=CC(N2CCNCC2)=CC=C1NS(=O)(=O)C1=CC=CC(F)=C1 QPUFHIPBJRUGOU-UHFFFAOYSA-N 0.000 claims 1
- IJZHBOUVMUVKPN-QGOAFFKASA-N n-[2-[[(e)-2-phenylethenyl]sulfonylamino]-5-piperazin-1-ylphenyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1/C=C/S(=O)(=O)NC1=CC=C(N2CCNCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 IJZHBOUVMUVKPN-QGOAFFKASA-N 0.000 claims 1
- RQSXWTIKILELLD-UHFFFAOYSA-N n-[2-[benzenesulfonyl(ethyl)amino]-4-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)N(CC)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 RQSXWTIKILELLD-UHFFFAOYSA-N 0.000 claims 1
- HCLQSFNUFYGOPJ-UHFFFAOYSA-N n-[2-[benzenesulfonyl(ethyl)amino]-4-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(CC)C1=CC(N2CCN(C)CC2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 HCLQSFNUFYGOPJ-UHFFFAOYSA-N 0.000 claims 1
- JQSROWAMCOAXKN-UHFFFAOYSA-N n-[2-[benzenesulfonyl(methyl)amino]-4-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)N(C)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 JQSROWAMCOAXKN-UHFFFAOYSA-N 0.000 claims 1
- YTEYXRVZHOKRQR-UHFFFAOYSA-N n-[2-[benzenesulfonyl(methyl)amino]-5-(1,4-diazepan-1-yl)phenyl]-4-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)N(C)C1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=C(C)C=C1 YTEYXRVZHOKRQR-UHFFFAOYSA-N 0.000 claims 1
- HTIDWAKPMVVSJG-UHFFFAOYSA-N n-[2-[ethyl-(3-fluorophenyl)sulfonylamino]-4-(4-methylpiperazin-1-yl)phenyl]-3-fluorobenzenesulfonamide Chemical compound C=1C=CC(F)=CC=1S(=O)(=O)N(CC)C1=CC(N2CCN(C)CC2)=CC=C1NS(=O)(=O)C1=CC=CC(F)=C1 HTIDWAKPMVVSJG-UHFFFAOYSA-N 0.000 claims 1
- DDQIYTCVKDBHTQ-UHFFFAOYSA-N n-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide Chemical compound NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 DDQIYTCVKDBHTQ-UHFFFAOYSA-N 0.000 claims 1
- PTNYOQRNLMUNCP-UHFFFAOYSA-N n-[2-amino-5-(4-methyl-1,4-diazepan-1-yl)phenyl]benzenesulfonamide Chemical compound C1CN(C)CCCN1C1=CC=C(N)C(NS(=O)(=O)C=2C=CC=CC=2)=C1 PTNYOQRNLMUNCP-UHFFFAOYSA-N 0.000 claims 1
- BXWFCFGBYXGFBJ-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-2-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CC1=CC=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(C)(=O)=O BXWFCFGBYXGFBJ-UHFFFAOYSA-N 0.000 claims 1
- DSKVIVKXGMWLPW-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-3,5-dimethyl-1,2-oxazole-4-sulfonamide;hydrochloride Chemical compound Cl.CC1=NOC(C)=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(C)(=O)=O DSKVIVKXGMWLPW-UHFFFAOYSA-N 0.000 claims 1
- QUBISYLUMIHISN-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-3-(trifluoromethyl)benzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 QUBISYLUMIHISN-UHFFFAOYSA-N 0.000 claims 1
- GPZADXDSUWFZAJ-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-3-methoxybenzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=CC(S(=O)(=O)NC=2C(=CC(=CC=2)N2CCNCCC2)NS(C)(=O)=O)=C1 GPZADXDSUWFZAJ-UHFFFAOYSA-N 0.000 claims 1
- DWNIJQDAHACGQF-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-4-(trifluoromethoxy)benzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 DWNIJQDAHACGQF-UHFFFAOYSA-N 0.000 claims 1
- IZJDSXPYJIGXSC-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-4-fluorobenzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1 IZJDSXPYJIGXSC-UHFFFAOYSA-N 0.000 claims 1
- YZKZNXKEILWBSH-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-4-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(C)(=O)=O YZKZNXKEILWBSH-UHFFFAOYSA-N 0.000 claims 1
- MHDNIIFIXQMKSV-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]-4-nitrobenzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 MHDNIIFIXQMKSV-UHFFFAOYSA-N 0.000 claims 1
- PFZSHSDQRXQRMX-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 PFZSHSDQRXQRMX-UHFFFAOYSA-N 0.000 claims 1
- VBMQIWFDKQQRLF-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C=1C=C(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C(NS(=O)(=O)C)=CC=1N1CCCNCC1 VBMQIWFDKQQRLF-UHFFFAOYSA-N 0.000 claims 1
- CNOXKMJLZGWSAF-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]naphthalene-2-sulfonamide;hydrochloride Chemical compound Cl.C=1C=C(NS(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C(NS(=O)(=O)C)=CC=1N1CCCNCC1 CNOXKMJLZGWSAF-UHFFFAOYSA-N 0.000 claims 1
- RHLRJEOCEVHSSL-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[(3-fluorophenyl)sulfonylamino]phenyl]-3-fluorobenzenesulfonamide;hydrochloride Chemical compound Cl.FC1=CC=CC(S(=O)(=O)NC=2C(=CC(=CC=2)N2CCNCCC2)NS(=O)(=O)C=2C=C(F)C=CC=2)=C1 RHLRJEOCEVHSSL-UHFFFAOYSA-N 0.000 claims 1
- HPSHQVBPGMTJFS-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[ethyl(methylsulfonyl)amino]phenyl]-3,4-dimethoxybenzenesulfonamide;hydrochloride Chemical compound Cl.CCN(S(C)(=O)=O)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C(OC)C(OC)=C1 HPSHQVBPGMTJFS-UHFFFAOYSA-N 0.000 claims 1
- GOOBZFVEEZKGKZ-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[ethyl(methylsulfonyl)amino]phenyl]-4-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CCN(S(C)(=O)=O)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 GOOBZFVEEZKGKZ-UHFFFAOYSA-N 0.000 claims 1
- NUVGANLKRZGKKD-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[ethyl(methylsulfonyl)amino]phenyl]quinoline-7-sulfonamide;hydrochloride Chemical compound Cl.C=1C=C(NS(=O)(=O)C=2C=C3N=CC=CC3=CC=2)C(N(CC)S(C)(=O)=O)=CC=1N1CCCNCC1 NUVGANLKRZGKKD-UHFFFAOYSA-N 0.000 claims 1
- YCPANVLPEOYUNL-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[methyl(methylsulfonyl)amino]phenyl]-4-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)N(C)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 YCPANVLPEOYUNL-UHFFFAOYSA-N 0.000 claims 1
- YVWKKDYBLDOCQN-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[methyl(methylsulfonyl)amino]phenyl]-5-pyridin-2-ylthiophene-2-sulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)N(C)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C(S1)=CC=C1C1=CC=CC=N1 YVWKKDYBLDOCQN-UHFFFAOYSA-N 0.000 claims 1
- ZEUYNSOKZSGTJU-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[methyl(methylsulfonyl)amino]phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)N(C)C1=CC(N2CCNCCC2)=CC=C1NS(=O)(=O)C1=CC=CC=C1 ZEUYNSOKZSGTJU-UHFFFAOYSA-N 0.000 claims 1
- OWIYCPKRHAFIGE-UHFFFAOYSA-N n-[4-(1,4-diazepan-1-yl)-2-[methyl(methylsulfonyl)amino]phenyl]naphthalene-1-sulfonamide;hydrochloride Chemical compound Cl.C=1C=C(NS(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C(N(C)S(C)(=O)=O)=CC=1N1CCCNCC1 OWIYCPKRHAFIGE-UHFFFAOYSA-N 0.000 claims 1
- DHBNBIHGOOLDDS-UHFFFAOYSA-N n-[4-(4-methylpiperazin-1-yl)-2-(quinolin-7-ylsulfonylamino)phenyl]quinoline-8-sulfonamide Chemical compound C1CN(C)CCN1C(C=C1NS(=O)(=O)C=2C=C3N=CC=CC3=CC=2)=CC=C1NS(=O)(=O)C1=CC=CC2=CC=CN=C12 DHBNBIHGOOLDDS-UHFFFAOYSA-N 0.000 claims 1
- HPWAWHCBDKJWMS-UHFFFAOYSA-N n-[4-[[2-(benzenesulfonamido)-4-(4-methylpiperazin-1-yl)phenyl]sulfamoyl]-2-chlorophenyl]acetamide Chemical compound C1CN(C)CCN1C(C=C1NS(=O)(=O)C=2C=CC=CC=2)=CC=C1NS(=O)(=O)C1=CC=C(NC(C)=O)C(Cl)=C1 HPWAWHCBDKJWMS-UHFFFAOYSA-N 0.000 claims 1
- SWNOCPKUGYCXBV-UHFFFAOYSA-N n-[5-(1,4-diazepan-1-yl)-2-(methanesulfonamido)phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.CS(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 SWNOCPKUGYCXBV-UHFFFAOYSA-N 0.000 claims 1
- KPFUAXHHXMLTLY-UGAWPWHASA-N n-[5-(1,4-diazepan-1-yl)-2-[[(e)-2-phenylethenyl]sulfonylamino]phenyl]benzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1/C=C/S(=O)(=O)NC1=CC=C(N2CCNCCC2)C=C1NS(=O)(=O)C1=CC=CC=C1 KPFUAXHHXMLTLY-UGAWPWHASA-N 0.000 claims 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims 1
- 230000006103 sulfonylation Effects 0.000 claims 1
- 238000005694 sulfonylation reaction Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101659A SE0101659D0 (sv) | 2001-05-11 | 2001-05-11 | New compounds |
| SE0101660A SE0101660D0 (sv) | 2001-05-11 | 2001-05-11 | New compounds |
| US29410201P | 2001-05-29 | 2001-05-29 | |
| US29413201P | 2001-05-29 | 2001-05-29 | |
| SE0101958A SE0101958D0 (sv) | 2001-06-05 | 2001-06-05 | New compounds |
| PCT/SE2002/000906 WO2002092585A1 (en) | 2001-05-11 | 2002-05-08 | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010157953A Division JP2011016801A (ja) | 2001-05-11 | 2010-07-12 | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534755A JP2004534755A (ja) | 2004-11-18 |
| JP2004534755A5 true JP2004534755A5 (enExample) | 2005-12-22 |
| JP4597480B2 JP4597480B2 (ja) | 2010-12-15 |
Family
ID=27532724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589470A Expired - Fee Related JP4597480B2 (ja) | 2001-05-11 | 2002-05-08 | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
| JP2010157953A Withdrawn JP2011016801A (ja) | 2001-05-11 | 2010-07-12 | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010157953A Withdrawn JP2011016801A (ja) | 2001-05-11 | 2010-07-12 | 肥満、ｉｉ型糖尿病およびｃｎｓ疾患の処置のための新規アリールスルホンアミド化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7173035B2 (enExample) |
| EP (1) | EP1406884A1 (enExample) |
| JP (2) | JP4597480B2 (enExample) |
| KR (1) | KR20090092832A (enExample) |
| CN (1) | CN1329382C (enExample) |
| AU (1) | AU2002303061B2 (enExample) |
| BR (1) | BR0209558A (enExample) |
| CA (1) | CA2443724C (enExample) |
| EA (1) | EA009647B1 (enExample) |
| IL (3) | IL158593A0 (enExample) |
| MX (1) | MXPA03010232A (enExample) |
| NO (1) | NO326690B1 (enExample) |
| NZ (1) | NZ528450A (enExample) |
| PL (1) | PL366619A1 (enExample) |
| WO (1) | WO2002092585A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
| US7718650B2 (en) * | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| AU2002344231B9 (en) * | 2001-05-29 | 2006-01-12 | The Procter & Gamble Company | Skin care kit |
| KR20090019894A (ko) | 2001-06-11 | 2009-02-25 | 바이오비트럼 에이비(피유비엘) | 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형 당뇨병 치료용 약제로서의 이들의 사용 방법 |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
| AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
| JP4538233B2 (ja) * | 2002-02-28 | 2010-09-08 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性障害治療用の、アミノ置換されたスルホンアニリド及びその誘導体 |
| US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| NZ552282A (en) * | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
| GB0224830D0 (en) | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
| SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| EP2415760A3 (en) * | 2003-02-20 | 2012-02-22 | Encysive Pharmaceuticals, Inc. | CCR-9 antagonists |
| US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
| US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
| US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
| AU2004265243A1 (en) * | 2003-06-20 | 2005-02-24 | Arena Pharmaceuticals, Inc. | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c receptor associated diseases |
| US20050201965A1 (en) * | 2004-03-11 | 2005-09-15 | The Procter & Gamble Company | Personal cleansing compositions |
| US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
| JP2007537275A (ja) | 2004-05-12 | 2007-12-20 | ケモセントリックス， インコーポレイテッド | アリールスルホンアミド |
| CA2584502A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | 2-methylpropanamides and their use as pharmaceuticals |
| EP1758882A4 (en) * | 2004-06-24 | 2008-01-23 | Incyte Corp | AMID COMPOUNDS AND THEIR USE AS MEDICAMENTS |
| CA2580690A1 (en) * | 2004-10-21 | 2006-05-04 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
| CA2588567A1 (en) * | 2004-12-13 | 2006-06-22 | Arena Pharmaceuticals, Inc. | N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| EP1695971A1 (en) * | 2004-12-30 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| EP1676842A1 (en) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments |
| EP1856075A1 (en) * | 2005-01-25 | 2007-11-21 | Epix Delaware, Inc. | Substituted arylamine compounds and their use as 5-ht6 modulators |
| EA200801551A1 (ru) * | 2006-01-20 | 2009-02-27 | Смитклайн Бичем Корпорейшн | Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы |
| CN101421234A (zh) * | 2006-04-19 | 2009-04-29 | 艾博特股份有限两合公司 | 适于治疗对5-羟色胺5ht6受体调节有反应的病症的杂环芳基砜 |
| US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
| WO2009137597A1 (en) * | 2008-05-06 | 2009-11-12 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF |
| WO2010051064A1 (en) * | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
| CN102459197B (zh) | 2009-04-30 | 2015-08-19 | Abbvie公司 | 适用于治疗响应血清素5-ht6受体的调节的病症的n-苯基-(哌嗪基或高哌嗪基)-苯磺酰胺或苯磺酰基-苯基-(哌嗪或高哌嗪)化合物 |
| US8362010B2 (en) | 2009-04-30 | 2013-01-29 | Abbott Gmbh & Co. Kg | Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| MX2011011519A (es) | 2009-04-30 | 2012-01-30 | Abbott Gmbh & Co Kg | Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. |
| US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
| WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
| WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2033597A5 (en) * | 1969-02-28 | 1970-12-04 | Ugine Kuhlmann | Green phthalocyanine metal dyes |
| DE2334562A1 (de) * | 1973-07-07 | 1975-01-30 | Hoechst Ag | Basisch substituierte benzol-1,3-disulfonamide und verfahren zu ihrer herstellung |
| NL7310889A (enExample) * | 1972-08-12 | 1974-02-14 | ||
| DE2239846A1 (de) * | 1972-08-12 | 1974-02-14 | Hoechst Ag | Basisch substituierte benzol-1,3disulfonamide und verfahren zu ihrer herstellung |
| DE2459394A1 (de) * | 1974-12-16 | 1976-06-24 | Hoechst Ag | Basisch substituierte benzol-1,3- disulfonamide und verfahren zu ihrer herstellung |
| CA1331757C (en) * | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
| DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| AU732096B2 (en) * | 1996-08-15 | 2001-04-12 | Schering Corporation | Ether muscarinic antagonists |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| JP2002511097A (ja) * | 1997-07-11 | 2002-04-09 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下６▼レセプターアンタゴニストであるスルホンアミド誘導体およびその製造方法 |
| GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| EP1053227B1 (en) * | 1998-01-29 | 2008-11-05 | Amgen Inc. | Ppar-gamma modulators |
| GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| US6943159B1 (en) * | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
| KR20010070997A (ko) * | 1998-07-20 | 2001-07-28 | 플레믹 크리스티안 | 비페닐 유도체 |
| GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| DE19941559A1 (de) * | 1999-09-01 | 2001-03-15 | Aventis Pharma Gmbh | Verwendung von Bissulfonamiden zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidömie |
| DE50011035D1 (de) * | 1999-09-01 | 2005-09-29 | Aventis Pharma Gmbh | Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US6399617B1 (en) * | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
| NZ528450A (en) | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
-
2002
- 2002-05-08 NZ NZ528450A patent/NZ528450A/en unknown
- 2002-05-08 WO PCT/SE2002/000906 patent/WO2002092585A1/en not_active Ceased
- 2002-05-08 CA CA002443724A patent/CA2443724C/en not_active Expired - Fee Related
- 2002-05-08 EP EP02769640A patent/EP1406884A1/en not_active Withdrawn
- 2002-05-08 CN CNB028096142A patent/CN1329382C/zh not_active Expired - Fee Related
- 2002-05-08 AU AU2002303061A patent/AU2002303061B2/en not_active Ceased
- 2002-05-08 BR BR0209558-0A patent/BR0209558A/pt not_active IP Right Cessation
- 2002-05-08 PL PL02366619A patent/PL366619A1/xx not_active Application Discontinuation
- 2002-05-08 KR KR1020097014381A patent/KR20090092832A/ko not_active Ceased
- 2002-05-08 EA EA200301232A patent/EA009647B1/ru not_active IP Right Cessation
- 2002-05-08 JP JP2002589470A patent/JP4597480B2/ja not_active Expired - Fee Related
- 2002-05-08 IL IL15859302A patent/IL158593A0/xx unknown
- 2002-05-08 MX MXPA03010232A patent/MXPA03010232A/es not_active Application Discontinuation
- 2002-05-10 US US10/143,335 patent/US7173035B2/en not_active Expired - Fee Related
- 2002-05-13 US US10/144,677 patent/US6969710B2/en not_active Expired - Fee Related
-
2003
- 2003-10-23 IL IL158593A patent/IL158593A/en not_active IP Right Cessation
- 2003-11-10 NO NO20034996A patent/NO326690B1/no not_active IP Right Cessation
-
2005
- 2005-08-30 US US11/215,173 patent/US7566715B2/en not_active Expired - Fee Related
- 2005-08-30 US US11/214,523 patent/US7319097B2/en not_active Expired - Fee Related
-
2008
- 2008-10-27 IL IL194950A patent/IL194950A0/en unknown
-
2010
- 2010-07-12 JP JP2010157953A patent/JP2011016801A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534755A5 (enExample) | ||
| RU2499795C2 (ru) | Антагонисты гистаминовых н3-рецепторов | |
| RU2006101458A (ru) | 2-аминобензотиазолы в качестве обратных агонистов рецепторов cb1 | |
| RU2388476C2 (ru) | Фармацевтическая композиция, содержащая производные бензодиазепина и ингибитор белка слияния rsv | |
| IL295487A (en) | gcn2 modulator compounds | |
| RU2001114978A (ru) | N-ариламиды антраниловой кислоты и тиоантраниловой кислоты | |
| JP2005522438A5 (enExample) | ||
| NZ585085A (en) | Method of treating arthritis using arylsulfonamide compounds | |
| CA2334298A1 (en) | Neuropeptide y5 receptor antagonists | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| RU2003114740A (ru) | Азотсодержащие ароматические производные | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| MX2007008279A (es) | Compuestos de arilamina sustituidos y su uso como moduladores de la 5-ht6. | |
| JP2015517981A5 (enExample) | ||
| JP2011529037A5 (enExample) | ||
| CA2526430A1 (en) | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | |
| JP2010540452A5 (enExample) | ||
| KR970703333A (ko) | 5-HT_1A 길항제로서의 피페라진 유도체(Piperazine derivatives as 5-HT_1A antagonists) | |
| JP2005524609A5 (enExample) | ||
| AU2005279088A1 (en) | Sulphonamide derivatives, their preparation and their therapeutic application | |
| JP2013525293A5 (enExample) | ||
| JP2009537542A5 (enExample) | ||
| JP2005522452A5 (enExample) | ||
| RU2004117543A (ru) | Амиды антраниловой кислоты и их применение в качестве ингибиторов тирозинкиназного рецептора фактора роста сосудистого эндотелия (vegf) | |
| US12576083B2 (en) | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer |